What is the recommended outpatient antibiotic regimen for an adult with low‑risk community‑acquired pneumonia?

Outpatient Antibiotic Treatment for Low-Risk Community-Acquired Pneumonia

For a previously healthy adult with low-risk community-acquired pneumonia, prescribe amoxicillin 1 g orally three times daily for 5–7 days as first-line therapy. This regimen provides 90–95% coverage of Streptococcus pneumoniae isolates, including many penicillin-resistant strains, and is the most effective oral agent for the predominant bacterial pathogen in CAP. 1, 2, 3

---

First-Line Therapy for Healthy Adults Without Comorbidities

• Amoxicillin 1 g orally three times daily for 5–7 days is the preferred first-line regimen, supported by strong recommendations and moderate-quality evidence from the American Thoracic Society and IDSA/ATS guidelines. 1, 2, 3
• Amoxicillin retains superior pneumococcal coverage compared with oral cephalosporins and is more cost-effective without sacrificing clinical outcomes. 1, 2

Acceptable Alternative

• Doxycycline 100 mg orally twice daily for 5–7 days is an acceptable alternative when amoxicillin is contraindicated, offering coverage of both typical bacterial pathogens (S. pneumoniae, H. influenzae, M. catarrhalis) and atypical organisms (Mycoplasma, Chlamydophila, Legionella). 1, 2, 3
• This carries a conditional recommendation with lower-quality evidence but remains guideline-endorsed. 1, 2

---

When to Avoid Macrolide Monotherapy

• Macrolide monotherapy (azithromycin or clarithromycin) should be reserved exclusively for regions where documented pneumococcal macrolide resistance is < 25%. 1, 2, 4, 3
• In most U.S. areas, macrolide resistance among S. pneumoniae is 20–30%, making macrolide monotherapy unsafe as first-line therapy in previously healthy adults. 1, 2, 3
• Macrolide monotherapy is associated with breakthrough bacteremia when resistant strains are present and should be avoided in areas with high resistance. 1, 2

---

Treatment Duration and Monitoring

• Treat for a minimum of 5 days and continue until the patient is afebrile for 48–72 hours with no more than one sign of clinical instability. 1, 2, 5, 3
• The typical total course for uncomplicated CAP is 5–7 days; extending therapy beyond this window does not improve outcomes and increases antimicrobial resistance risk. 1, 2, 5, 3
• Extended courses (14–21 days) are reserved only for infections caused by Legionella pneumophila, Staphylococcus aureus, or Gram-negative enteric bacilli. 1, 2, 3

Early Clinical Review

• Arrange a clinical review at 48 hours (or sooner if symptoms worsen) to assess symptom resolution, oral intake, and treatment response. 1, 2
• Indicators of treatment failure that warrant hospital referral include: no clinical improvement by day 2–3, development of respiratory distress (respiratory rate > 30/min, oxygen saturation < 92%), inability to tolerate oral antibiotics, or new complications such as pleural effusion. 1, 2

---

When to Escalate Therapy

• If amoxicillin monotherapy fails, add or substitute a macrolide (azithromycin 500 mg day 1, then 250 mg daily days 2–5, or clarithromycin 500 mg twice daily) to provide coverage for atypical pathogens. 1, 2, 4
• If combination therapy (β-lactam + macrolide/doxycycline) fails, switch to a respiratory fluoroquinolone (levofloxacin 750 mg daily or moxifloxacin 400 mg daily). 1, 2

---

Patients with Comorbidities or Recent Antibiotic Use

For adults with comorbidities (COPD, diabetes, chronic heart/liver/renal disease, malignancy, immunosuppression) or recent antibiotic exposure (within 90 days), combination therapy is mandatory.

• Preferred regimen: Amoxicillin-clavulanate 875 mg/125 mg orally twice daily plus azithromycin 500 mg day 1, then 250 mg daily for 5–7 days total. 1, 2, 4, 3
• This combination achieves 91.5% favorable clinical outcomes by covering both typical bacterial pathogens and atypical organisms. 1, 2

Alternative for Comorbid Patients

• Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg daily or moxifloxacin 400 mg daily for 5–7 days) is an acceptable alternative when β-lactams or macrolides are contraindicated. 1, 2, 3
• Fluoroquinolones should be reserved for patients with comorbidities or treatment failure due to FDA warnings about serious adverse events (tendon rupture, peripheral neuropathy, aortic dissection) and rising resistance. 1, 2, 3

---

Critical Pitfalls to Avoid

• Never use macrolide monotherapy in patients with comorbidities or in areas where pneumococcal macrolide resistance exceeds 25%. 1, 2, 4, 3
• Avoid indiscriminate fluoroquinolone use in uncomplicated outpatient CAP due to FDA safety warnings and resistance concerns; reserve for patients with comorbidities or documented treatment failure. 1, 2, 3
• Oral cephalosporins (cefuroxime, cefpodoxime) are not first-line agents due to inferior in-vitro activity against S. pneumoniae, lack of atypical coverage, higher cost, and no demonstrated clinical superiority. 1, 2
• Do not automatically extend therapy beyond 5–7 days in responding patients without specific indications; longer courses increase antimicrobial resistance risk without improving outcomes. 1, 2, 5, 3
• If the patient received antibiotics within the previous 90 days, select an agent from a different class to minimize resistance risk. 1, 2

---

Follow-Up and Prevention

• Schedule a routine follow-up visit at 6 weeks; obtain a chest radiograph only if symptoms persist, physical signs remain abnormal, or the patient has high risk for underlying malignancy (e.g., smokers > 50 years). 1, 2
• Offer pneumococcal polysaccharide vaccination to all adults ≥ 65 years and those with high-risk conditions. 1, 2
• Recommend annual influenza vaccination for all patients. 1, 2
• Provide smoking-cessation counseling to all current smokers. 1, 2